{"id":"NCT01763827","sponsor":"Amgen","briefTitle":"Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2","officialTitle":"A Double-blind, Randomized, Placebo and Ezetimibe-controlled, Multicenter Study to Evaluate Safety and Efficacy of Lipid Lowering Monotherapy With AMG 145 in Subjects With a 10-Year Framingham Risk Score of 10% or Less","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-01-21","primaryCompletion":"2013-10-10","completion":"2013-10-29","firstPosted":"2013-01-09","resultsPosted":"2015-12-30","lastUpdate":"2022-11-08"},"enrollment":615,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hyperlipidemia"],"interventions":[{"type":"BIOLOGICAL","name":"Evolocumab","otherNames":["AMG 145","Repatha"]},{"type":"DRUG","name":"Ezetimibe","otherNames":["Zetia"]},{"type":"BIOLOGICAL","name":"Placebo to Evolocumab","otherNames":[]},{"type":"OTHER","name":"Placebo to Ezetimibe","otherNames":[]}],"arms":[{"label":"Placebo Q2W","type":"PLACEBO_COMPARATOR"},{"label":"Placebo QM","type":"PLACEBO_COMPARATOR"},{"label":"Ezetimibe (Q2W)","type":"ACTIVE_COMPARATOR"},{"label":"Ezetimibe (QM)","type":"ACTIVE_COMPARATOR"},{"label":"Evolocumab Q2W","type":"EXPERIMENTAL"},{"label":"Evolocumab QM","type":"EXPERIMENTAL"}],"summary":"The primary objective was to evaluate the effect of 12 weeks of evolocumab subcutaneous (SC) monotherapy every 2 weeks (Q2W) and monthly (QM), compared with placebo and ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in adults with a 10-year Framingham risk score of 10% or less.","primaryOutcome":{"measure":"Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Placebo Q2W","deltaMin":0.1,"sd":1.67},{"arm":"Placebo QM","deltaMin":-1.34,"sd":1.54},{"arm":"Ezetimibe (Q2W)","deltaMin":-17.75,"sd":1.67},{"arm":"Ezetimibe (QM)","deltaMin":-18.57,"sd":1.56},{"arm":"Evolocumab Q2W","deltaMin":-57.04,"sd":1.23},{"arm":"Evolocumab QM","deltaMin":-56.12,"sd":1.12}],"pValues":[{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG001 vs OG005","p":"<0.001"},{"comp":"OG002 vs OG004","p":"<0.001"},{"comp":"OG003 vs OG005","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":83,"countries":["United States","Australia","Belgium","Canada","Denmark","France","South Africa","South Korea","Taiwan","Turkey (TÃ¼rkiye)"]},"refs":{"pmids":["24691094","33325247","32564340","29736889","29353350","30755061","30120772","28249876","32114889","29768954","30852766"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":76},"commonTop":["Headache","Diarrhoea","Nasopharyngitis"]}}